All News
Ab1113 #ACR22 Remibrutinib (LOU064, BTK inhib) in Sjogren's
Will there be new Rx for Sjo?
T Dorner: 73 pts Ph2 BTK 100mg BID/100 QD/PBO
Better ESSDAI at wk 24 (p=0.003)
Unstim saliv flow: improved vs PBO, not stat signif
Decreased CXCL13 chemokine
PROs not improved
@RheumNow https://t.co/hJp33JPpHt
Eric Dein ericdeinmd ( View Tweet)
FOREMOST results: Early oligoarticular PsA pts experienced high disease burden/decreased QoL. Small joint involvement, although less commonly seen in oligoarticular PsA, was the most frequently observed pattern. Abs 1018 #ACR22 @RheumNow https://t.co/wBldKM9MTq https://t.co/qOVZd8aTyR
Dr. Rachel Tate uptoTate ( View Tweet)
"If I had one test in a difficult case of suspected PMR, it would be PET/CT" - @LCalabreseDO
#ACR22 @RheumNow
(credit: as heard by @drceowen) https://t.co/w88peUd4j1
David Liew drdavidliew ( View Tweet)
Mx aging rheumatic dx pt
🌟5M approach🌟
🧠Mind (mood/cog)
💊 Medication (polypharm)
🏃 Mobility
👉Multicomplexity (biopsychsoc)
💪🏻 Matters (aligning 2 specific goals)
💥Interdisciplinary💥
#GeriRheum #ACR22 @RheumNow @B_Buehring_MD @UnaMakris
Patricia Harkins DrTrishHarkins ( View Tweet)
Read my new article on @RheumNow #ACR22 https://t.co/ByJ1yrrdj6
Links:
TheDaoIndex KDAO2011 ( View Tweet)
DANBIO registry plenary Abs 1112 finds 1 yr retention following a mandatory nationwide infliximab biosimilar-to-biosimilar switch was high. Retention higher in originator-experienced and in pts w/ low disease activity. #ACR22 @RheumNow https://t.co/ZAV2dcVzXl https://t.co/Kti2bZ1pkZ
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR22 Plenary II. Abstr#1113 Promising news in #Sjogren. Phase 2 RCT showed oral BTK-i Remibrutinib improved ESSDAI score vs Placebo (delta -2.8) & salivary flow at Wks 24. ESSPRI unchanged. No major safety concern. Look forward to Phase 3 results soon @RheumNow #ACRBest https://t.co/z0oy9FvheY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sjogren's in a Plenary! Remibrutinib (BTKi) in SjS
Improved ESSDAI at wk 24, but NONE on ESSPRI (more patient-centric ie fatigue, dryness, joint pain)
Definitely helps w/lab abnormalities, but worried benefit for outcomes that matter may be limited
#ACR22 @RheumNow abstr#1113 https://t.co/GutY8KndbR
Mike Putman EBRheum ( View Tweet)
Post hoc analysis of 3 PsA/SPA trials: no effect of tobacco 🚬 on TOFA efficacy But numerically higher TEAEs
Contrasting w/ data from real world TNF
Interesting data but small sample size & events N
https://t.co/gv8uvcThMD
Abs#1036 #ACR22 @Rheumnow https://t.co/HCJT0XF1tg
Aurelie Najm AurelieRheumo ( View Tweet)
Interesting Abs 0825: MAS was most often caused 2nd to a benign disease. Most common presentation: fever w/ cytopenias. Ferritin levels more than 7511 and ferritin/ CRP levels more than 204.5 ass'd w/ higher mortality. #ACR22 @RheumNow https://t.co/HEuMedE9Rh https://t.co/6f4bf7x9Hh
Dr. Rachel Tate uptoTate ( View Tweet)
Initial Remibrutinib (oral, covalent, and highly specific inhibitor of Bruton’s tyrosine kinase (BTK)) data in SS shows good efficacy and safety. Plenary Abs 1113 #ACR22 @RheumNow https://t.co/5Zr0Y1ueAv https://t.co/Iy194YUWNC
Dr. Rachel Tate uptoTate ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
DANBIO registry: 1600+ pts RA, AxSpA, PsA
Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111)
Maintenance at 1yr:
>80%
> withdrawal in original IFX naive, but higher BL DA
Do second time switchers do better because of past switch experience?
Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz
Aurelie Najm AurelieRheumo ( View Tweet)
2nd Plenary Session!
Remibrutinib (BTK inhibitor) for treatment of Sjögren's syndrome (phase 2 study)
Improvement of ESSDAI, salivary flow and pathologically elevated Ig's
Abs#1113 @RheumNow #ACR22 https://t.co/vdgxBPe6qd
Robert B Chao, MD doctorRBC ( View Tweet)
We're used to originator-to-biosimilar switches.
Widespread biosim use means we now see biosim-biosim switches (incl as second switch)
DANBIO data
retention good
I see the hallmarks of nocebo still an issue
I think we can all agree: ongoing education important
#ACR22 @RheumNow https://t.co/6PcMfEEozk
David Liew drdavidliew ( View Tweet)
Yes. But this only accounts for 1/3 of risk to develop clinical RA.
We need a better understanding of the other 2/3 so we can propose efficient preventive interventions.
#ACR22 @RheumNow https://t.co/RRzlAISFK3
Aurelie Najm AurelieRheumo ( View Tweet)
@EBRheum @RheumNow Its more than that…tubulointerstitial kidney disease, lymph nodes, salivary gland, and hepatobiliary tract disease don’t show findings of vasculitis.
Certain HLA haplotypes more linked with autoimmune diseases are present.
#ACR
@RheumNow
Fabio Torres FabioTorressav ( View Tweet)
@AlexisOgdie et al: PsA pts who were MDA, DAPSA LDA, or ACR50 responders vs non-responders reported clinically meaningful improvements across PROs including pain, physical function, fatigue, and work productivity. Abs 1019 #ACR22 @RheumNow https://t.co/MK13sXS3Or https://t.co/TfCrQMV2JX
Dr. Rachel Tate uptoTate ( View Tweet)
Presence of DFS pattern should not be used to indiscriminately exclude presence of a rheumatic disease based on retrospective study in Abs 0814. RA, SS and Raynaud's ICD10 codes were higher among DFS pattern ANA per chart review. #ACR22 @RheumNow https://t.co/mLtppvR4dk https://t.co/6Lukxntqe7
Dr. Rachel Tate uptoTate ( View Tweet)
Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA.
Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity.
@RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M
Robert B Chao, MD doctorRBC ( View Tweet)
